CR9897A - Metodo de produccion proteica utilizando carnosina - Google Patents

Metodo de produccion proteica utilizando carnosina

Info

Publication number
CR9897A
CR9897A CR9897A CR9897A CR9897A CR 9897 A CR9897 A CR 9897A CR 9897 A CR9897 A CR 9897A CR 9897 A CR9897 A CR 9897A CR 9897 A CR9897 A CR 9897A
Authority
CR
Costa Rica
Prior art keywords
carnosine
cell culture
production method
protein production
senescence compound
Prior art date
Application number
CR9897A
Other languages
English (en)
Inventor
Yen-Tung Luan
Wenge Wang
Paul Thoday
Denis Drapeau
Judy Chou
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37873105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9897A publication Critical patent/CR9897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan metodos para producir una proteina en cultivo celular que comprende un compuesto anti-senescencia, tal como el antioxidante carnosina. De acuerdo con las ensenanzas de la presente invencion, las celulas cultivadas en un medio de cultivo celular que comprende un compuesto anti-senescencia exhiben mayor viabilidad y productividad. Adicionalmente, los cultivos celulares cultivados en presencia de un compuesto anti-senescencia exhiben niveles reducidos de agregados de elevado peso molecular en el medio de cultivo celular.
CR9897A 2005-10-24 2008-04-18 Metodo de produccion proteica utilizando carnosina CR9897A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72957305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
CR9897A true CR9897A (es) 2008-07-29

Family

ID=37873105

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9897A CR9897A (es) 2005-10-24 2008-04-18 Metodo de produccion proteica utilizando carnosina

Country Status (23)

Country Link
US (1) US20070110743A1 (es)
EP (1) EP1941026B1 (es)
JP (2) JP2009512459A (es)
KR (1) KR101402634B1 (es)
CN (1) CN101297027B (es)
AR (1) AR058140A1 (es)
AU (1) AU2006306433B2 (es)
BR (1) BRPI0617744A2 (es)
CA (1) CA2627003C (es)
CR (1) CR9897A (es)
DK (1) DK1941026T3 (es)
EC (1) ECSP088395A (es)
ES (1) ES2485374T3 (es)
IL (1) IL190550A (es)
NI (1) NI200800111A (es)
NO (1) NO20081622L (es)
PE (1) PE20070796A1 (es)
PL (1) PL1941026T3 (es)
PT (1) PT1941026E (es)
RU (1) RU2491347C2 (es)
SI (1) SI1941026T1 (es)
TW (1) TW200736397A (es)
WO (1) WO2007050498A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3255141T3 (da) 2006-07-13 2022-01-31 Wyeth Llc Fremstilling af antistoffer med forbedret glycosyleringsmønster
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
TWI610936B (zh) * 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
WO2011018472A2 (en) 2009-08-14 2011-02-17 Basf Se Methods in cell cultures, and related inventions, employing certain additives
WO2012019160A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
SG187885A1 (en) * 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TW201247874A (en) * 2011-05-25 2012-12-01 United Biomedical Inc Method for producing the activity of bone activating protein
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
MX360649B (es) * 2013-03-13 2018-11-12 Anteis Sa Péptidos para el rejuvenecimiento de la piel y métodos de uso de los mismos.
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
BR112015021993A8 (pt) * 2013-03-15 2019-12-03 Genentech Inc polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN104398398A (zh) * 2014-10-27 2015-03-11 陈少威 一种细胞量子动力素(平衡剂)及其使用方法
MA40864A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
WO2017120359A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
BR112020003122A2 (pt) * 2017-10-16 2020-08-04 Regeneron Pharmaceuticals, Inc. métodos e sistemas para controlar condições de meio de cultura celular e para reduzir modificações pós-translação de uma proteína secretada
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2025053166A1 (ja) * 2023-09-05 2025-03-13 味の素株式会社 培地組成物
WO2025142807A1 (ja) * 2023-12-25 2025-07-03 武田薬品工業株式会社 細胞の培養方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69132032T2 (de) * 1990-11-23 2000-12-21 Peptech Ltd., North Ryde Verzögerung, verhinderung und/oder rückgängigmachen von zellalterung
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
RU2245365C2 (ru) * 1994-01-03 2005-01-27 Генентек Инк. Тромбопоэтин
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
RU2134120C1 (ru) * 1995-06-26 1999-08-10 Безруков Михаил Васильевич Средство для стабилизации пептидной связи в белковом препарате
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
EP2305027B1 (en) * 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
OA13092A (en) * 2001-04-24 2006-11-10 Innogenetics Nv Constructs and methods for expression of recombinant HCV envelope proteins.
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
PT1678208E (pt) * 2003-10-27 2013-07-10 Wyeth Llc Remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatite
WO2005064013A1 (en) 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents

Also Published As

Publication number Publication date
NO20081622L (no) 2008-06-18
PL1941026T3 (pl) 2014-12-31
US20070110743A1 (en) 2007-05-17
JP5907928B2 (ja) 2016-04-26
BRPI0617744A2 (pt) 2011-08-02
SI1941026T1 (sl) 2014-07-31
CN101297027A (zh) 2008-10-29
EP1941026A2 (en) 2008-07-09
AU2006306433B2 (en) 2013-04-18
CA2627003C (en) 2018-08-28
WO2007050498A3 (en) 2007-07-12
PE20070796A1 (es) 2007-08-15
WO2007050498A2 (en) 2007-05-03
NI200800111A (es) 2009-03-03
DK1941026T3 (da) 2014-07-21
HK1120552A1 (en) 2009-04-03
RU2491347C2 (ru) 2013-08-27
KR101402634B1 (ko) 2014-06-03
JP2013165728A (ja) 2013-08-29
RU2008113220A (ru) 2009-12-10
CA2627003A1 (en) 2007-05-03
ES2485374T3 (es) 2014-08-13
CN101297027B (zh) 2013-04-03
TW200736397A (en) 2007-10-01
PT1941026E (pt) 2014-07-31
ECSP088395A (es) 2008-05-30
EP1941026B1 (en) 2014-06-04
JP2009512459A (ja) 2009-03-26
KR20080063365A (ko) 2008-07-03
AU2006306433A1 (en) 2007-05-03
AR058140A1 (es) 2008-01-23
IL190550A (en) 2017-01-31
IL190550A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
CR9897A (es) Metodo de produccion proteica utilizando carnosina
PA8778001A1 (es) Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia
AR090822A1 (es) Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos
CO6501191A2 (es) Medio de cultivo celular para expresión de la proteina adamts
MX384291B (es) Modificación genética de ratas.
WO2008060541A3 (en) In vitro expansion of postpartum-derived cells using microcarriers
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
EP2588594A4 (en) PROCESS FOR CULTIVATING UNDIFFERENCED CELLS USING DELAYED RELATED COMPOSITION COMPOSITIONS
AR095462A1 (es) Composiciones y métodos para la producción y administración de arn
MX2013014937A (es) Cultivo de celulas de mamifero.
WO2010096588A3 (en) Cell culture media containing combinations of proteins
CO6440530A2 (es) Formulaciones de caldo de fermentación
CR11827A (es) Activadores de glucoquinasa
WO2014143744A3 (en) Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same
MX362866B (es) Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn.
MX360779B (es) Composiciones de cultivo celular con antioxidantes y métodos para la producción de polipéptidos.
EA201170024A1 (ru) Способы получения высокой плотности жизнеспособных клеток в культуре клеток млекопитающих
CR20160307A (es) Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
UY32732A (es) Medios para cultivo de células de mamíferos que comprenden sobrenadante del fraccionamiento de cohn y uso de los mismos
EP2435558A4 (en) GENETICALLY CORRECTED NON-DISABLED INDUCED PLURIPOTENTER STEM CELLS
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
ES2530694T3 (es) Factor de permisividad celular para virus, y usos del mismo
MX2024009056A (es) Metodos para mejorar la viabilidad celular en un biorreactor de produccion.
CY1112746T1 (el) Κρυοσυντηρηση ηπατοκυτταρων

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)